Lymphocyte-depleting induction therapy lowers the risk of acute rejection in African American pediatric kidney transplant recipients

2016 ◽  
Vol 21 (1) ◽  
pp. e12823 ◽  
Author(s):  
Cole N. Crowson ◽  
Rhiannon D. Reed ◽  
Brittany A. Shelton ◽  
Paul A. MacLennan ◽  
Jayme E. Locke
Keyword(s):  
African American ◽  
Acute Rejection ◽  
Kidney Transplant ◽  
Induction Therapy ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

Induction Therapy with Basiliximab versus Thymoglobulin in African-American Kidney Transplant Recipients

2005 ◽  
Vol 79 (6) ◽  
pp. 716-721 ◽  
Author(s):  
Abdolreza Haririan ◽  
Katherina Morawski ◽  
Dale H. Sillix ◽  
Jose M. El-Amm ◽  
James Garnick ◽  
...  
Keyword(s):  
African American ◽  
Kidney Transplant ◽  
Induction Therapy ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

Comparison of efficacy of induction therapy in low immunologic risk African-American kidney transplant recipients

2009 ◽  
Vol 23 (5) ◽  
pp. 500-505 ◽  
Author(s):  
James N. Fleming ◽  
David J. Taber ◽  
Nicole A. Weimert ◽  
Maria F. Egidi ◽  
John McGillicuddy ◽  
...  
Keyword(s):  
African American ◽  
Kidney Transplant ◽  
Induction Therapy ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

scholarly journals African-American Race Modifies the Influence of Tacrolimus Concentrations on Acute Rejection and Toxicity in Kidney Transplant Recipients

2015 ◽  
Vol 35 (6) ◽  
pp. 569-577 ◽  
Author(s):  
David J. Taber ◽  
Mulugeta G. Gebregziabher ◽  
Titte R. Srinivas ◽  
Kenneth D. Chavin ◽  
Prabhakar K. Baliga ◽  
...  
Keyword(s):  
African American ◽  
Acute Rejection ◽  
Kidney Transplant ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
African American Race

Pretransplant Serum CXCL9 and CXCL10 Levels Fail to Predict Acute Rejection in Kidney Transplant Recipients Receiving Induction Therapy

2011 ◽  
Vol 91 (8) ◽  
pp. e59-e61 ◽  
Author(s):  
Sebastiaan Heidt ◽  
Sushma Shankar ◽  
Anand S.R. Muthusamy ◽  
David San Segundo ◽  
Kathryn J. Wood
Keyword(s):  
Acute Rejection ◽  
Kidney Transplant ◽  
Induction Therapy ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

scholarly journals Cytolytic Induction Therapy Improves Clinical Outcomes in African-American Kidney Transplant Recipients

2017 ◽  
Vol 266 (3) ◽  
pp. 450-456 ◽  
Author(s):  
David J. Taber ◽  
John W. McGillicuddy ◽  
Charles F. Bratton ◽  
Vinayak S. Rohan ◽  
Satish Nadig ◽  
...  
Keyword(s):  
African American ◽  
Clinical Outcomes ◽  
Kidney Transplant ◽  
Induction Therapy ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

Immunosuppressive Management of Pediatric Kidney Transplant Recipients

2020 ◽  
Vol 26 (28) ◽  
pp. 3451-3459
Author(s):  
Tomáš Seeman
Keyword(s):  
Immunosuppressive Therapy ◽  
Kidney Transplant ◽  
Induction Therapy ◽  
Graft Loss ◽  
Calcineurin Inhibitors ◽  
Mtor Inhibitors ◽  
Therapeutic Drug ◽  
High Dose ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

: Kidney transplantation is a preferable treatment of children with end-stage kidney disease. All kidney transplant recipients, including pediatric need immunosuppressive medications to prevent rejection episodes and graft loss. : Induction therapy is used temporarily only immediately following transplantation while maintenance immunosuppressive drugs are started and given long-term. There is currently no consensus regarding the use of induction therapy in children; its use should be decided based on the immunological risk of the child. : The recent progress shows that the recommended strategy is to use as maintenance immunosuppressive therapy a combination of a calcineurin inhibitor (preferably tacrolimus) with an antiproliferative drug (preferably mycophenolate mofetil) with steroids that can be withdrawn early or late in low-risk children. The mTOR-inhibitors (sirolimus, everolimus) are used rarely in pediatrics because of common side effects and no evidence of a benefit over calcineurin inhibitors. The use of calcineurin inhibitors, mycophenolate, and mTOR-inhibitors should be followed by therapeutic drug monitoring. : Immunosuppressive therapy of acute rejection consists of high-dose steroids and/or anti-lymphocyte antibodies (T-cell mediated rejection) or plasma exchange, intravenous immunoglobulines and/or rituximab (antibodymediated rejection). : The future strategies for research are mainly precise characterisation of children needing induction therapy, more specific indications for mTOR-inhibitors and for the far future, the possibility to reach the immuno tolerance.

Sign in / Sign up

Export Citation Format

Share Document